All Updates

All Updates

icon
Filter
Funding
Triplebar receives USD 1 million investment from Rabobank
Cell-cultured Meat
Jan 9, 2024
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Product updates
Funding
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Cell-cultured Meat

Cell-cultured Meat

Jan 9, 2024

Triplebar receives USD 1 million investment from Rabobank

Funding

  • Triplebar, a biotech company specializing in low-cost animal proteins and cell lines for cultivated meats, has secured a USD 1 million investment from Rabobank, a cooperative Dutch bank.

  • The funding will be used for accelerating innovation in the biotech and food tech sectors, aiming to address issues like food security and environmental challenges.

  • Analyst QuickTake: The new cash injection, along with Triplebar’s last funding round , brings the total funds raised by the company to USD 21 million. The company has developed a hyper-throughput screening platform capable of examining 10,000x more biological samples than conventional platforms, allowing for expedited innovation.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.